Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Spruce Biosciences management to meet with Oppenheimer » 04:55
05/18/22
05/18
04:55
05/18/22
04:55
SPRB

Spruce Biosciences

$1.47 /

+0.14 (+10.53%)

Meeting to be held in New…

Meeting to be held in New York on May 18 hosted by Oppenheimer.

ShowHide Related Items >><<
SPRB Spruce Biosciences
$1.47 /

+0.14 (+10.53%)

SPRB Spruce Biosciences
$1.47 /

+0.14 (+10.53%)

03/08/22 Ladenburg
Spruce Biosciences initiated with a Buy at Ladenburg
12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
SPRB Spruce Biosciences
$1.47 /

+0.14 (+10.53%)

SPRB Spruce Biosciences
$1.47 /

+0.14 (+10.53%)

Conference/Events
Spruce Biosciences management to meet with Oppenheimer » 16:49
05/16/22
05/16
16:49
05/16/22
16:49
SPRB

Spruce Biosciences

$1.33 /

-0.035 (-2.56%)

Meeting to be held in New…

Meeting to be held in New York on May 18 hosted by Oppenheimer.

ShowHide Related Items >><<
SPRB Spruce Biosciences
$1.33 /

-0.035 (-2.56%)

SPRB Spruce Biosciences
$1.33 /

-0.035 (-2.56%)

03/08/22 Ladenburg
Spruce Biosciences initiated with a Buy at Ladenburg
12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
SPRB Spruce Biosciences
$1.33 /

-0.035 (-2.56%)

SPRB Spruce Biosciences
$1.33 /

-0.035 (-2.56%)

Earnings
Spruce Biosciences reports Q1 EPS (50c), consensus (46c) » 16:02
05/11/22
05/11
16:02
05/11/22
16:02
SPRB

Spruce Biosciences

$1.31 /

-0.1 (-7.09%)

"Throughout the…

"Throughout the first quarter of 2022, we continued to drive our clinical and business objectives forward, with key progress made in our lead program for adults with classic congenital adrenal hyperplasia (CAH), expansion of our executive leadership team, and through potential access to non-dilutive sources of capital. We were pleased to achieve the recent milestone of 25% enrollment in our CAHmelia-203 study for adult classic CAH, which keeps us on track to meet topline data readout for the study in the second half of 2023," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. "The enhanced protocols we rolled-out for the CAHmelia-203 and 204 studies have been well-received by study investigators across our global trial sites and have streamlined screening activities. We look forward to continuing this momentum and providing further enrollment updates over the course of the year."

ShowHide Related Items >><<
SPRB Spruce Biosciences
$1.31 /

-0.1 (-7.09%)

SPRB Spruce Biosciences
$1.31 /

-0.1 (-7.09%)

03/08/22 Ladenburg
Spruce Biosciences initiated with a Buy at Ladenburg
12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
SPRB Spruce Biosciences
$1.31 /

-0.1 (-7.09%)

SPRB Spruce Biosciences
$1.31 /

-0.1 (-7.09%)

Hot Stocks
Spruce Biosciences appoints Libbie Mansell Chief Regulatory and Quality Officer » 08:09
04/11/22
04/11
08:09
04/11/22
08:09
SPRB

Spruce Biosciences

$2.01 /

-0.11 (-5.19%)

Spruce Biosciences…

Spruce Biosciences announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company's global regulatory affairs and quality strategy. "Dr. Mansell brings extensive regulatory affairs and quality expertise at precisely the right time for Spruce, as we progress tildacerfont through clinical development for adults and children with classic congenital adrenal hyperplasia and women with polycystic ovary syndrome," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. "With more than 30 years of life sciences industry experience and a successful track record of managing complex drug development programs for numerous biopharmaceutical companies, Dr. Mansell is a strong addition to our executive team. We look forward to her leadership and guidance as we continue to advance our pipeline of novel treatments for patients with rare endocrine disorders."

ShowHide Related Items >><<
SPRB Spruce Biosciences
$2.01 /

-0.11 (-5.19%)

SPRB Spruce Biosciences
$2.01 /

-0.11 (-5.19%)

03/08/22 Ladenburg
Spruce Biosciences initiated with a Buy at Ladenburg
12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
SPRB Spruce Biosciences
$2.01 /

-0.11 (-5.19%)

SPRB Spruce Biosciences
$2.01 /

-0.11 (-5.19%)

Over a quarter ago
Hot Stocks
Coherus Biosciences appoints Dias as Chief Medical Officer » 08:10
03/15/22
03/15
08:10
03/15/22
08:10
CHRS

Coherus Biosciences

$12.05 /

-0.265 (-2.15%)

, SPRB

Spruce Biosciences

$1.87 /

-0.025 (-1.32%)

Coherus BioSciences…

Coherus BioSciences (CHRS) announced Rosh Dias, MD, MRCP, has been appointed Chief Medical Officer. Dr. Dias will serve as a member of the Company's executive leadership team and oversee a number of clinical functions including medical affairs, clinical operations, pharmacovigilance and clinical development. Dr. Dias joins Coherus most recently from Spruce Biosciences (SPRB) where he was the Chief Medical Officer.

ShowHide Related Items >><<
SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

CHRS Coherus Biosciences
$12.05 /

-0.265 (-2.15%)

CHRS Coherus Biosciences
$12.05 /

-0.265 (-2.15%)

03/07/22 JPMorgan
JPMorgan downgrades Coherus on FDA Chinese PD-1 'pivot'
03/07/22 JPMorgan
Coherus Biosciences downgraded to Neutral from Overweight at JPMorgan
02/22/22 Barclays
Coherus Biosciences price target lowered to $20 from $24 at Barclays
02/07/22 JPMorgan
Coherus Biosciences price target lowered to $20 from $23 at JPMorgan
SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

03/08/22 Ladenburg
Spruce Biosciences initiated with a Buy at Ladenburg
12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

CHRS Coherus Biosciences
$12.05 /

-0.265 (-2.15%)

SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

Earnings
Spruce Biosciences reports Q4 EPS (39c), consensus (54c) » 16:11
03/14/22
03/14
16:11
03/14/22
16:11
SPRB

Spruce Biosciences

$1.87 /

-0.025 (-1.32%)

Cash, cash equivalents…

Cash, cash equivalents and investments as of December 31, 2021, were $121.4 million, which management anticipates funds the company into the second quarter of 2024. "Over the last quarter, we have made notable progress in our efforts to advance new treatment options for people living with rare endocrine disorders and to maximize the potential of tildacerfont as a therapeutic to treat people living with classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS)," said Javier Szwarcberg, CEO. "We are expanding the number of study sites globally and rolling out updated protocols for the CAHmelia-203 and CAHmelia-204 clinical trials in adult classic CAH, which we expect will accelerate patient enrollment. We were also pleased to initiate our Phase 2 clinical trials in patients with pediatric classic CAH and PCOS and expect topline results from both studies by the first half of 2023."

ShowHide Related Items >><<
SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

03/08/22 Ladenburg
Spruce Biosciences initiated with a Buy at Ladenburg
12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

Hot Stocks
Spruce Biosciences names Will Charlton as Chief Medical Officer » 16:01
03/14/22
03/14
16:01
03/14/22
16:01
SPRB

Spruce Biosciences

$1.87 /

-0.025 (-1.32%)

Spruce Biosciences…

Spruce Biosciences "announced that Will Charlton, M.D., M.A.S., has been appointed Chief Medical Officer, and will succeed Rosh Dias, M.D., who has stepped down to pursue other opportunities. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of clinical research experience in industry and academia and will lead the company's clinical development and global drug development strategy."

ShowHide Related Items >><<
SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

03/08/22 Ladenburg
Spruce Biosciences initiated with a Buy at Ladenburg
12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
SPRB Spruce Biosciences
$1.87 /

-0.025 (-1.32%)

Initiation
Spruce Biosciences initiated with a Buy at Ladenburg » 06:51
03/08/22
03/08
06:51
03/08/22
06:51
SPRB

Spruce Biosciences

$1.88 /

-0.115 (-5.76%)

Ladenburg Thalmann…

Ladenburg Thalmann analyst Aydin Huseynov initiated coverage of Spruce Biosciences with a Buy rating and $6 price target. With many biotech companies trading below cash, Spruce Biosciences "is standing out" as a company that develops a small molecule for a rare disease congenital adrenal hyperplasia with a mechanism of action that was validated by a large biopharma company, Huseynov tells investors in a research note. The analyst sees a 30% probability of success of tildacerfont in the CAH indication.

ShowHide Related Items >><<
SPRB Spruce Biosciences
$1.88 /

-0.115 (-5.76%)

SPRB Spruce Biosciences
$1.88 /

-0.115 (-5.76%)

12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
11/23/21 Cowen
Spruce Biosciences downgraded to Market Perform from Outperform at Cowen
SPRB Spruce Biosciences
$1.88 /

-0.115 (-5.76%)

Conference/Events
Oppenheimer biotech/pharma analysts to hold analyst/industry conference call » 12:35
03/04/22
03/04
12:35
03/04/22
12:35
NBIX

Neurocrine

$87.60 /

-0.055 (-0.06%)

, BBIO

BridgeBio

$7.76 /

-0.13 (-1.65%)

, CMX

Caremark RX

/

+

, SPRB

Spruce Biosciences

$2.09 /

-0.02 (-0.95%)

Biotech/Pharmaceuticals…

Biotech/Pharmaceuticals Analysts review the landscape and treatment for Congenital Adrenal Hyperplasia (CAH) and relevant for NBIX, BBIO, CRNX and SPRB on an Analyst/Industry conference call to be held on March 4 at 1 pm.

ShowHide Related Items >><<
SPRB Spruce Biosciences
$2.09 /

-0.02 (-0.95%)

NBIX Neurocrine
$87.60 /

-0.055 (-0.06%)

BBIO BridgeBio
$7.76 /

-0.13 (-1.65%)

NBIX Neurocrine
$87.60 /

-0.055 (-0.06%)

03/03/22 Piper Sandler
Neurocrine downgraded after psychiatrist survey at Piper Sandler
03/03/22 Piper Sandler
Neurocrine downgraded to Neutral from Overweight at Piper Sandler
02/24/22 Goldman Sachs
Neurocrine upgraded to Buy from Neutral at Goldman Sachs
02/14/22 Mizuho
Neurocrine price target lowered to $95 from $103 at Mizuho
BBIO BridgeBio
$7.76 /

-0.13 (-1.65%)

01/03/22 Piper Sandler
Alnylam upgraded to Overweight from Neutral at Piper Sandler
12/30/21 BofA
Alnylam remains top pick for 2022 at Bofa amid recent volatility
12/28/21 Stifel
Stifel sees no obvious explanation for BridgeBio ATTRibute-CM study failure
12/28/21 Oppenheimer
Ionis weakness associated with peer ATTR failure 'misplaced,' says Oppenheimer
CMX Caremark RX
/

+

SPRB Spruce Biosciences
$2.09 /

-0.02 (-0.95%)

12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
11/23/21 Cowen
Spruce Biosciences downgraded to Market Perform from Outperform at Cowen
NBIX Neurocrine
$87.60 /

-0.055 (-0.06%)

BBIO BridgeBio
$7.76 /

-0.13 (-1.65%)

NBIX Neurocrine
$87.60 /

-0.055 (-0.06%)

SPRB Spruce Biosciences
$2.09 /

-0.02 (-0.95%)

NBIX Neurocrine
$87.60 /

-0.055 (-0.06%)

BBIO BridgeBio
$7.76 /

-0.13 (-1.65%)

BBIO BridgeBio
$7.76 /

-0.13 (-1.65%)

Conference/Events
Oppenheimer biotech/pharma analysts to hold analyst/industry conference call » 04:55
03/04/22
03/04
04:55
03/04/22
04:55
NBIX

Neurocrine

$87.68 /

-4.18 (-4.55%)

, BBIO

BridgeBio

$7.90 /

-0.37 (-4.47%)

, CMX

Caremark RX

/

+

, SPRB

Spruce Biosciences

$2.11 /

-0.04 (-1.86%)

Biotech/Pharmaceuticals…

Biotech/Pharmaceuticals Analysts review the landscape and treatment for Congenital Adrenal Hyperplasia (CAH) and relevant for NBIX, BBIO, CRNX and SPRB on an Analyst/Industry conference call to be held on March 4 at 1 pm.

ShowHide Related Items >><<
SPRB Spruce Biosciences
$2.11 /

-0.04 (-1.86%)

NBIX Neurocrine
$87.68 /

-4.18 (-4.55%)

BBIO BridgeBio
$7.90 /

-0.37 (-4.47%)

NBIX Neurocrine
$87.68 /

-4.18 (-4.55%)

03/03/22 Piper Sandler
Neurocrine downgraded after psychiatrist survey at Piper Sandler
03/03/22 Piper Sandler
Neurocrine downgraded to Neutral from Overweight at Piper Sandler
02/24/22 Goldman Sachs
Neurocrine upgraded to Buy from Neutral at Goldman Sachs
02/14/22 Mizuho
Neurocrine price target lowered to $95 from $103 at Mizuho
BBIO BridgeBio
$7.90 /

-0.37 (-4.47%)

01/03/22 Piper Sandler
Alnylam upgraded to Overweight from Neutral at Piper Sandler
12/30/21 BofA
Alnylam remains top pick for 2022 at Bofa amid recent volatility
12/28/21 Stifel
Stifel sees no obvious explanation for BridgeBio ATTRibute-CM study failure
12/28/21 Oppenheimer
Ionis weakness associated with peer ATTR failure 'misplaced,' says Oppenheimer
CMX Caremark RX
/

+

SPRB Spruce Biosciences
$2.11 /

-0.04 (-1.86%)

12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
11/23/21 Cowen
Spruce Biosciences downgraded to Market Perform from Outperform at Cowen
NBIX Neurocrine
$87.68 /

-4.18 (-4.55%)

BBIO BridgeBio
$7.90 /

-0.37 (-4.47%)

NBIX Neurocrine
$87.68 /

-4.18 (-4.55%)

SPRB Spruce Biosciences
$2.11 /

-0.04 (-1.86%)

NBIX Neurocrine
$87.68 /

-4.18 (-4.55%)

BBIO BridgeBio
$7.90 /

-0.37 (-4.47%)

BBIO BridgeBio
$7.90 /

-0.37 (-4.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.